Carcinoma, Bronchogenic  >>  Caprelsa (vandetanib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

10 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Caprelsa (vandetanib) / Sanofi
NCT00252746: ZD6474 Phase IIa Dose Finding Multicentre Study

Completed
2a
53
Japan
ZD6474 (vandetanib) 100mg, ZACTIMA™, ZD6474 (vandetanib) 200mg, ZACTIMA, ZD6474 (vandetanib) 300mg
Genzyme, a Sanofi Company
Non Small Cell Lung Carcinoma
01/07
01/07
NCT00047840: This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.

Completed
2
129
US, Europe
ZD6474, Placebo, Docetaxel
Genzyme, a Sanofi Company
Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line
 
09/06
NCT00066313: ZD6474 in Treating Patients With Small Cell Lung Cancer

Completed
2
Canada
vandetanib, adjuvant therapy
Genzyme, a Sanofi Company
Lung Cancer
12/06
12/06
NCT00059722: This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.

Completed
2
160
US, Europe, RoW
ZD6474, Placebo, ZD1839
Genzyme, a Sanofi Company
Carcinoma, Non-Small-Cell Lung
 
06/07
NCT00071188: ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Completed
2
US, Europe, RoW
ZD6474, Paclitaxel, Carboplatin
Genzyme, a Sanofi Company
Carcinoma, Non-Small-Cell Lung
10/07
10/07
NCT00459121: Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery

Terminated
2
2
US
carboplatin, Paraplatin ®, paclitaxel, Taxol ®, Onxal TM, Zactima, Caprelsa, ZD6474, Vandetanib, neoadjuvant therapy, R0 Resection
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)
Lung Cancer
01/08
10/08
NCT00777179: Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy

Checkmark Maintenance for advanced or metastatic NSCLC following first-line platinum-doublet chemotherapy
Oct 2013 - Oct 2013: Maintenance for advanced or metastatic NSCLC following first-line platinum-doublet chemotherapy
Checkmark Interim P2 data - WCLC
Jun 2011 - Jun 2011: Interim P2 data - WCLC
Completed
2
117
RoW
Vandetanib, Zactima TM, Placebo
Genzyme, a Sanofi Company
NSCLC
01/10
12/11
NCT00687297: Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer

Checkmark +/placebo as maintenance for pts with adv NSCLC
May 2013 - May 2013: +/placebo as maintenance for pts with adv NSCLC
Checkmark P2 Data - WCLC
Jun 2011 - Jun 2011: P2 Data - WCLC
Checkmark P2 Data
More
Completed
2
162
US
vandetanib induction, ZD6474, Docetaxel, Taxotere, Carboplatin, Placebo, Vandetanib maintenance
PrECOG, LLC., AstraZeneca
Lung Cancer, Non Small Cell Lung Cancer
01/11
04/11
ZELIG, NCT00753714 / 2007-004521-22: Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus Gemcitabine

Checkmark As first-line treatment of adv NSCLC in elderly pts
Apr 2014 - Apr 2014: As first-line treatment of adv NSCLC in elderly pts
Checkmark P2 data-ASCO
Jun 2012 - Jun 2012: P2 data-ASCO
Completed
2
124
Europe
ZD6474, Vandetanib, Zactima, Placebo to Match ZD6474, Vandetanib, Gemcitabine, Gemzar
Genzyme, a Sanofi Company
Non Small Cell Lung Cancer
04/11
12/11
NCT02087839: Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC): Phase II

Withdrawn
2
0
US
ZD6474 (ZACTIMA), Zactima, Vandetanib, Radiation Therapy, Radiation, XRT
M.D. Anderson Cancer Center, AstraZeneca
Non-Small Cell Lung Cancer
09/12
09/12

Download Options